SynthesisJournal of the American Academy of Dermatology2017
Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.
Synthesis in Journal of the American Academy of Dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Biologic-Induced Paradoxical Psoriatic Alopecia: A Systematic Review.The Australasian journal of dermatology · 2025Pooled it
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review.PloS one · 2024Pooled it
- Paradoxical psoriasis in axial spondyloarthritis and rheumatoid arthritis treated with b/tsDMARDs: a retrospective cohort study.Clinical rheumatology · 2026Article
- How Organ Manifestations Beyond the Bone May Guide Risk Stratification and Treatment Decisions in Chronic Nonbacterial Osteomyelitis.Paediatric drugs · 2026Review
- Kidney pathology findings in pediatric patients with kidney injury and inflammatory bowel disease: a case series.Pediatric nephrology (Berlin, Germany) · 2026Article
- [Cutaneous side effects of biologics: an important topic also in occupational dermatology].Dermatologie (Heidelberg, Germany) · 2026Article
- Bimekizumab-induced paradoxical palmoplantar pustular psoriasis.JAAD case reports · 2026Article
- Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab.Dermatology reports · 2026Article
- Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report.SAGE open medical case reports · 2026Article
- Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma - GASD syndrome by TNF antagonists.Frontiers in immunology · 2026Article
- Skin immune microenvironment in psoriasis: from bench to bedside.Frontiers in immunology · 2025Review
- Article
- Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review.The journal of allergy and clinical immunology. Global · 2024Article
- Insights into New-onset Arthritis in Patients with Hidradenitis Suppurativa.Acta dermato-venereologica · 2024Article
- Triggers for the onset and recurrence of psoriasis: a review and update.Cell communication and signaling : CCS · 2024Review
- Risk Factors for Psoriasis Flares: A Narrative Review.Psoriasis (Auckland, N.Z.) · 2024Review
- Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.Frontiers in immunology · 2024Article
- Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review.Dermatology and therapy · 2024Review
- Paradoxical psoriasis: The flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?Journal of translational autoimmunity · 2023Article
- Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature.Paediatric drugs · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTumor necrosis factor-α (TNF-α) inhibitors have been reported to induce new-onset psoriasis.
objectiveTo better define the demographic, clinical features, and treatment approach of TNF-α inhibitor-induced psoriasis.
methodsSystematic review of published cases of TNF-α inhibitor-induced psoriasis.
resultsWe identified 88 articles with 216 cases of new-onset TNF-α inhibitor-induced psoriasis. The mean age at psoriasis onset was 38.5 years. The most common underlying diseases were Crohn disease (40.7%) and rheumatoid arthritis (37.0%). Patients underwent TNF-α therapy for an average of 14.0 months before psoriasis onset with 69.9% of patients experiencing onset within the first year. The majority of patients received skin-directed therapy, though patients who discontinued TNF therapy had the greatest resolution of symptoms (47.7%) compared with those who switched to a different TNF agent (36.7%) or continued therapy (32.9%). LIMITATIONS: Retrospective review that relies on case reports and series.
conclusionWhile TNF-α inhibitor cessation may result in resolution of induced psoriasis, lesions may persist. Decisions regarding treatment should be weighed against the treatability of TNF-α inhibitor-induced psoriasis, the severity of the background rheumatologic or gastrointestinal disease, and possible loss of efficacy with cessation followed by retreatment. Skin-directed therapy is a reasonable initial strategy except in severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.